奧翔藥業(603229.SZ):與STADA簽訂合作開發和商業化戰略合作協議
格隆匯11月4日丨奧翔藥業(603229.SZ)公佈,公司於2021年11月3日經董事會批准與STADA Arzneimittel AG(簡稱“STADA”)簽訂了《合作開發和商業化戰略合作協議》,雙方着眼於未來全球醫藥產業發展前景,就化學仿製藥製劑產品聯合開發及全球化營銷開展長期全面合作。
目前雙方首期選定項目研發投資預算金額為2350萬歐元,在合作區域的國家將由雙方共同承擔相關費用(50%/50%),對公司相關年度的業績影響需視後續項目研發和項目實施進展而定。
STADA作為一家全球化藥企,在全球約120個國家銷售其產品。STADA專注於三塊業務領域,包括仿製藥、專業製藥和非處方消費保健產品,具有非常豐富的醫藥產品研發、生產、銷售經驗。公司通過與STADA的此次合作,有助於推進公司製劑國際化進程,提升公司製劑的國際化水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.